

Sumitomo Pharma ESG Data Table

*The data are basically as of the end of the fiscal year on a non-consolidated basis.

Organizational Governance

Reported Items	Unit	FY2022	FY2021	FY2020
Management Structure				
Executive Committee	Times	11	11	11
Board of Directors	Times	18	22	21
Attendance Rate of Board of Directors	%	99.21	98.96	100
Directors	Persons	9	9	8
Of which, Outside Directors	Persons	4	4	3
Of which, Female Directors	Persons	1	1	1
Amount of Remuneration and the Like	Millions of Yen	326	392	391
Principal Activities of Outside Directors				
Yutaka Atomi		—	He attended all twenty-two (22) meetings held by the Board of Directors during the fiscal year under review, and made statements at those meetings, primarily from the professional standpoint of a medical doctor.	He attended all twenty-one (21) meetings held by the Board of Directors during the fiscal year under review, and made statements at those meetings, primarily from the professional standpoint of a medical doctor.
Saeko Arai		She attended all eighteen (18) meetings held by the Board of Directors during the fiscal year under review, and made statements at those meetings, primarily based on her extensive experience as a corporate executive and from the professional standpoint of a certified public accountant.	She attended all twenty-two (22) meetings held by the Board of Directors during the fiscal year under review, and made statements at those meetings, primarily based on her extensive experience as a corporate executive and from the professional standpoint of a certified public accountant.	She attended all twenty-one (21) meetings held by the Board of Directors during the fiscal year under review, and made statements at those meetings, primarily based on her extensive experience as a corporate executive and from the professional standpoint of a certified public accountant.
Nobuhiro Endo		He attended all eighteen (18) meetings held by the Board of Directors during the fiscal year under review, and made statements at those meetings, primarily based on his extensive experience and a broad perspective as a corporate executive.	He attended all twenty (20) of the twenty-two (22) meetings held by the Board of Directors during the fiscal year under review, and made statements at those meetings, primarily based on his extensive experience and broad perspective as a corporate executive.	He attended all twenty-one (21) meetings held by the Board of Directors during the fiscal year under review, and made statements at those meetings, primarily based on his extensive experience and broad perspective as a corporate executive.
Minoru Usui		He attended all eighteen (18) meetings held by the Board of Directors during the fiscal year under review, and made statements at those meetings, primarily based on his extensive experience and broad perspective as a corporate executive.	He attended all seventeen (17) meetings held by the Board of Directors during the fiscal year under review after his assumption of office as a Director, and made statements at those meetings, primarily based on his extensive experience and broad perspective as a corporate executive.	—
Koji Fujimoto		He attended all fifteen (15) meetings held by the Board of Directors during the fiscal year under review after his assumption of office as a Director, and made statements at those meetings, primarily based on his extensive experience and broad perspective in the healthcare field at administrative organizations.	—	—
Audit System				
Audit & Supervisory Board	Times	13	13	13
Audit & Supervisory Board Members	Persons	5	5	5
Of which, Outside Audit & Supervisory Board Members	Persons	3	3	3
Amount of Remuneration and the like	Millions of Yen	93	89	87
Full-time Staff of Corporate Audits' Office	Persons	1	1	1

Sumitomo Pharma ESG Data Table

*The data are basically as of the end of the fiscal year on a non-consolidated basis.

Principal Activities of Outside Audit Supervisory Board				
Junsuke Fujii		—	He attended all twenty-two (22) meetings held by the Board of Directors and all thirteen (13) meetings held by the Audit & Supervisory Board during the fiscal year under review. He made statements at those meetings, primarily based on his extensive experience and broad perspective as a corporate executive.	He attended twenty (20) meetings out of the twenty-one (21) meetings held by the Board of Directors and all thirteen (13) meetings held by the Audit & Supervisory Board during the fiscal year under review. He made statements at those meetings, primarily based on his extensive experience and broad perspective as a corporate executive.
Yoshio Iteya		He attended seventeen (17) meetings out of the eighteen (18) meetings held by the Board of Directors and all thirteen (13) meetings held by the Audit & Supervisory Board during the fiscal year under review. He made statements at those meetings, primarily from the professional standpoint of an attorney.	He attended all twenty-two (22) meetings held by the Board of Directors and all thirteen (13) meetings held by the Audit & Supervisory Board during the fiscal year under review. He made statements at those meetings, primarily from the professional standpoint of an attorney.	He attended all twenty-one (21) meetings held by the Board of Directors and all thirteen (13) meetings held by the Audit & Supervisory Board during the fiscal year under review. He made statements at those meetings, primarily from the professional standpoint of an attorney.
Mayumi Mochizuki		She attended seventeen (17) meetings out of the eighteen (18) meetings held by the Board of Directors and all thirteen (13) meetings held by the Audit & Supervisory Board during the fiscal year under review. She made statements at those meetings, primarily from the professional standpoint as a pharmacologist.	She attended eleven (11) meetings out of the seventeen (17) meetings held by the Board of Directors and eight (8) meetings out of the ten (10) meetings held by the Audit & Supervisory Board during the fiscal year under review after her assumption of office as an Audit & Supervisory Board Member. She made statements at those meetings, primarily from the professional standpoint as a pharmacologist.	—
Daishiro Michimori		He attended all fifteen (15) meetings held by the Board of Directors and all ten (10) meetings held by the Audit & Supervisory Board during the fiscal year under review after his assumption of office as an Audit & Supervisory Board Member. He made statements at those meetings, primarily from the professional standpoint of an expert in financial and accounting affairs and of an	—	—
Communication about Compliance				
Corporate CSR Blog	Articles	2	3	6
Framework for Compliance Implementation				
Periodic Report at Board of Directors	Times	1	1	1
Compliance Committee	Times	1	1	1
Compliance Committee of Group Companies in Japan	Times	1	1	1
Compliance Committee of Group Companies outside Japan	Times	1	1	1
Whistle-blowing Systems, Consultation Desks				
Systems for All Employees	Systems	6	7	7
Consulted Issues	Cases	37	41	44
Compliance Education and Training				
Compliance Trainings for All Employees	Times	5	2	1
Compliance Workshops Held at the Workplace Level for All Workplaces	Times	1	1	1
Compliance Workshops Held at the Group Companies for all Group Companies	Times	1	1	1
Harmful Incident Concerning Pharmaceuticals Workshops for All Workplaces	Times	1	1	1
Information Security Training for All Employees	Times	1	1	1
Stress Check for All Employees	Times	1	1	1
Mental Health Manager Workshops	Times	1	1	1

Sumitomo Pharma ESG Data Table

*The data are basically as of the end of the fiscal year on a non-consolidated basis.

Mental Health Self-care Workshops	Times	1	1	1
Product Recall Training in Corporate Regulatory Compliance & Quality assurance Division	Times	1	1	0
Natural Disaster Training in Risk Management Related Divisions	Times	3	1	1
R&D Ethics e-Learning				
*For researchers who are recommended to take the course on the job	Times	1	1	1

Human Rights

Reported Items	Unit	FY2022	FY2021	FY2020
Initiative to Respect Human Rights				
Human Rights Workshops for All Employees	Times	1	1	1
Drug-induced Suffering Workshops for All Employees	Times	1	1	1
Supply Chain Human Rights Management Workshop	Times	0	0	0
Initiative to Prevent Harrasment				
Number of People in Charge of the General Consultation Desk	Staffs	2	2	2
Number of People in Charge of the Harassment Consultation Desk (Internal Company)	Staffs	General Desk, 3 Staffs Working Place Desk, 7 Sites, 17 Staffs	General Desk, 3 Staffs Working Place Desk, 7 Sites, 17 Staffs	General Desk, 3 Staffs Working Place Desk, 7 Sites, 17 Staffs
Number of People in Charge of the Harassment Consultation Desk (Workers Union)	Staffs	General Desk, 4 Staffs Working Place Desk, 11 Sites, 11 Staffs	General Desk, 5 Staffs Working Place Desk, 11 Sites, 11 Staffs	General Desk, 5 Staffs Working Place Desk, 11 Sites, 11 Staffs

Labour Practices

Reported Items	Unit	FY2022	FY2021	FY2020
Basic Human Resources Data				
Number of Employees (consolidated) *As of March 31	Persons	6,250	6,987	6,822
Men	Persons	3,718	4,147	4,119
Women	Persons	2,532	2,840	2,703
Proportion of Women	%	40.5	40.6	39.6
Number of Employees (non-consolidated) *As of March 31	Persons	3,026	3,040	3,067
Men	Persons	2,260	2,292	2,337
Women	Persons	766	748	730
Proportion of Women	%	25.3	24.6	23.8
Proportion of Female Managers *As of April 1 of the following fiscal year	%	14.4	16.0	14.6
Gender Wage Gap (all workers)	%	81.3	—	—
Gender Wage Gap (permanent workers)	%	82.5	—	—
Gender Wage Gap (part time workers and fixed-term workers)	%	79.0	—	—
MRs in Japan, Including Managers	Persons	1,140	1,220	1,270
MRs in Japan, Excluding Managers	Persons	1,040	1,110	1,150
Average Age	Age	43.8	43.4	43.1
Average Length of Continuous Employment	Years	18.3	18.0	17.8
Recruitment of New Graduates	Persons	70	64	66
Propotion of Women, New Graduates	%	51.4	53.1	47.0
Recruitment of Mid Carrer	Persons	41	29	44
Proportion of Recruitment of Mid Carrer	%	36.9	31.2	40.0
Employment Rate of Persons with Disabilities *As of June 1, every fiscal year	%	2.34	2.34	2.25
Employee Turnover Rate of Employees Leaving for Personal Reasons	%	2.67	1.68	1.17
Retention Rate of New Graduates 3 Years after Joining the Company	%	87.9	94.3	100.0
Labour Union Participating Rate Eligibility Conducted by Collective Agreement Article 3-1	%	100	100	100
Total Actual Working Hours per year	Hours	1849.5	1871.5	1862.3
Average Overtime Hours per month	Hours	4	4.1	3.3
Avarage Usage of Paid Leave	Days per a Employee	15.4	14.1	13
Paid Leave Acquisition Rate	%	77.5	70	64
Male Employees Taking Childcare Leave (note1)	Persons	95	83	32
Childcare Leave Usage Rate (Male Employees)	%	130.1	97.6	42.1
Female Employees Taking Childcare Leave	Persons	26	51	33
Utilization of Shorter Working Hours for Childcare	Persons	83	66	60
Utilization of Leave for Nursing Care	Persons	1	1	1
Utilization of Shorter Workdays for Nursing Care	Persons	2	1	2

Sumitomo Pharma ESG Data Table

*The data are basically as of the end of the fiscal year on a non-consolidated basis.

Mental Illness Leave (≥30days)	Persons	17	25	6
Health and Safety Management				
Stress Check for All Employees	Times	1	1	1
Mental Health Manager Workshops	Times	1	1	1
Mental Health Self-care Workshops	Times	1	1	1
No-Overtime Day at Workplace Level	Days	Established at Each Workplace	Established at Each Workplace	Established at Each Workplace
Whole Company No-Overtime Day	Days	1	1	1
Work-related Accident Frequency Rate (non-consolidated)	—	0.97	1.27	0.80
Work-related Accident Frequency Rate (non-consolidated) * Excluding Accidents Involving Business Vehicles	—	0.81	0.79	0.00
Lost-time Injuries Frequency Rate (non-consolidated)	—	0.32	0.16	0.00
Lost-time Injuries Frequency Rate (non-consolidated) * Excluding Accidents Involving Business Vehicles	—	0.16	0.16	0.00
Lost-time Injuries Frequency Rate (consolidated)	—	0.44	0.22	0.08
Lost-time Injuries Frequency Rate (contractors)	—	0.00	1.36	0.00
Fatalities (consolidated)	Persons	0	0	0
Fatalities (contractors)	Persons	0	0	0
Communication with Employees				
Employee Engagement Survey	Times	1	1	1
Response Rate	%	98.5	98.8	98.8
Opinions toward Management	Cases	757	778	1,063
Proposals Made to Address Issues and/or Offer Solutions at Respective Divisions/Departments	Cases	911	986	1,436

note:1 Regarding the gender wage gap, our wage system is based on the grade of the role (job) in which each employee is engaged, and there is no difference in base wages for male and female employees in the same grade; however, the following factors contribute to the differences in their average annual wages. Employees who do not receive their wages due to absenteeism, absence from work or temporary retirement are excluded from the calculation.

Among permanent workers, the fact that the percentage of female employees in general office work positions is higher than that of male employees is the main factor in the gender wage gap.

As for part time workers and fixed-term workers, the majority of them are part time workers; and, the wage levels for part time workers are lower than those for employees rehired after retirement and contract workers, due to reasons such as differences in job level and working hours. The fact that these part time workers are all female workers is a factor contributing to the gender wage gap.

note:2 The number of employees excluding seconded employees is listed.

Sumitomo Pharma ESG Data Table

*The data are basically as of the end of the fiscal year on a non-consolidated basis.

The Environment

Reported Items	Unit	FY2022	FY2021	FY2020
Environmental Management				
Environmental and Safety Committee	Times	2	3	2
Executive Environmental and Safety Board	Times	2	2	2
Environment, Health and Safety Audit	Business units	4	6	4
Follow-up Activities for Environmental and Safety Audit	Cases	8	16	10
Environmental Accidents	Incidents	0	0	0
Violation of Environmental Laws and Regulations Involving Criminal or Non-Criminal Fines	Incidents	0	0	0
Energy Consumption*1				
Total Energy Consumption	MWh	280,835	261,238	238,384
Non-renewable Energy Consumption	MWh	246,663	254,219	238,295
Renewable Energy Consumption	MWh	34,172	7,019	89
Amount of Purchased Electricity Derived from Renewable Energy Sources	MWh	34,083	6,933	-
Amount of Generated Electricity at the Solar Power Generating Systems*2	MWh	89	86	89
CO₂ Emissions				
Scope 1 (from Energy Sources) + Scope 2 (Market-Based) Total Emissions	t-CO ₂	54,347	61,749	58,267
Scope 1 (from Energy Sources) Emissions	t-CO ₂	27,829	21,398	19,514
Scope 2 (Market-Based) Emissions	t-CO ₂	26,518	40,351	38,753
Scope 3 Emissions*3	t-CO ₂	364,869	382,293	393,124
Category 1 (Purchased Goods and Services)*4	t-CO ₂	310,925	332,970	344,160
Category 2 (Capital goods)*4	t-CO ₂	24,134	19,015	19,669
Category 3 (Fuel- and Energy-Related Activities not Included in Scope 1 or Scope 2)*3	t-CO ₂	15,048	15,643	15,793
Category 4 (Upstream Transportation and Distribution)	t-CO ₂	853	824	860
Category 5 (Waste Generated in Operations)	t-CO ₂	3,655	4,466	1,943
Category 6 (Business Travel)	t-CO ₂	3,140	886	554
Category 7 (Employee Commuting)	t-CO ₂	634	651	732
Category 8 (Upstream Leased Assets)	t-CO ₂	-	-	-
Category 9 (Downstream Transportation and Distribution)*5	t-CO ₂	3,555	3,344	4,204
Category 10 (Processing of Sold Products)	t-CO ₂	-	-	-
Category 11 (Use of Sold Products)	t-CO ₂	2,521	4,065	4,770
Category 12 (End-of-Life Treatment of Sold Products)	t-CO ₂	302	323	335
Category 13 (Downstream Leased Assets)	t-CO ₂	103	106	104
Category 14 (Franchises)	t-CO ₂	-	-	-
Category 15 (Investments)	t-CO ₂	-	-	-
Amount of Water Withdrawal and Wastewater Discharged				
Total Amount of Water Withdrawal (consolidated)	t	847,157	873,171	889,692
Tap Water (consolidated)	t	342,057	397,701	341,140
Industrial Water (consolidated)	t	377,879	408,387	393,987
Ground Water (consolidated)*6	t	113,045	55,853	142,183
Other (consolidated)	t	14,176	11,230	12,382
Total Amount of Water Withdrawal (non-consolidated)	t	804,281	814,250	821,090
Tap Water (non-consolidated)	t	299,181	338,780	272,538
Industrial Water (non-consolidated)	t	377,879	408,387	393,987
Ground Water (non-consolidated)*6	t	113,045	55,853	142,183
Other (non-consolidated)	t	14,176	11,230	12,382
Total Amount of Water Discharged (consolidated)	t	843,300	866,398	883,402
River (consolidated)	t	589,817	604,448	616,743
Sewerage (consolidated)	t	253,483	261,950	266,659
Total Amount of Water Discharged (non-consolidated)	t	804,281	814,250	821,090
River (non-consolidated)	t	589,817	604,448	616,743
Sewerage (non-consolidated)	t	214,464	209,802	204,347
Raw Material Consumption				
Raw Materials for Products (Excluding Metals)	t	2,861	3,577	3,997
Raw Materials for Products (Metals)	t	1	0	10
Total Amount of Product Containers and Packaging Materials	t	590	642	658
Glass	t	53	55	54
Plastic	t	332	354	367
Paper	t	204	234	236
PRTR Substances and VOC Substances Handled				
PRTR Substances	t	958	1417	1545
VOC Substances	t	2,004	2,452	3,215
Waste				
Total Amount of Waste Generated	t	4,757	6,183	7,685
Amount Recycled	t	3,442	4,717	6,133
Recycling Rate	%	72	76	80
Amount of Final Disposal	t	14	18	56
Final Disposal Rate	%	0.3	0.3	0.7
Amount of Hazardous Waste Generated	t	3,603	5,196	6,402
Amount of Hazardous Waste Recycled	t	3,069	4,408	5,821
PRTR Substances	t	930	1,371	1,453
Waste Containing High Levels of PCB in Storage	Units	0	0	1

Sumitomo Pharma ESG Data Table

*The data are basically as of the end of the fiscal year on a non-consolidated basis.

Waste Containing Low Levels of PCB in Storage or in Use	Units	4	4	4
Released into the Atmosphere				
SO _x	t	0.2	0.3	0.2
NO _x	t	31.6	37.5	42.2
Dust Emissions	t	0.1	0.2	0.2
PRTR Substances	t	2.7	3.0	5.3
VOC Substances	t	14.8	17.3	22.8
Released into Water Systems				
BOD	t	0.2	0.2	0.2
COD	t	2.0	2.2	2.2
Phosphorus	t	0.1	0.1	0.1
Nitrogen	t	0.4	0.5	0.3
PRTR Substances	t	0.0	0.0	0.0
Environmental Accounting				
Environmental Investment	Millions of Yen	137	226	16
Environmental Expenditure	Millions of Yen	698	772	731
Economic Effect	Millions of Yen	3	3	3
Application of Environmental Conservation Systems				
Green Procurement (Green Purchasing Ratio of Office Supplies)	%	51	53	53
Green Logistics	Initiatives	39	46	67
Green Product Development	Initiatives	37	37	30
Green Facilities Design	Initiatives	16	13	15
Environmental Considerations for Business Vehicles				
Percentage of Business Vehicles Shifted to Hybrid Cars (Excluding Cold Regions)	%	100	100	100
Number of Electric Vehicles (EVs) in Our Business Vehicles	Vehicles	11	11	0
Communications with Group Companies				
Meeting to Exchange Information on Environment and Safety between Group Companies in Japan	Times	1	1	1
Environment, Health and Safety Audits Conducted for Group Companies in Japan	Companies	0	2	2
Environment, Health and Safety Audits Conducted for Group Companies Outside Japan	Companies	0	0	0
Biodiversity				
Owls Forest Restoration Project of Kishiwada City, Osaka	Times Participants	6 128	1 13 ^{*7}	2 20 ^{*7}

* 1: The unit of energy consumption was changed from TJ to MWh in FY2022. At this time, the units for previous years were also changed.

* 2: The amount of solar power generation from FY2020 to 2022 shows only the amount of solar power generation at the Central Research Laboratories due to measuring instrument failure at the Osaka Research Center.

* 3: Some of the figures for FY2020 and FY2021 have been corrected.

* 4: In Japanese Ministry of the Environment's "The database on emissions unit values for accounting of greenhouse gas emissions, etc. by organizations throughout the supply chain" (ver. 3.3), it was (newly) specified that the consumption tax is included in the emission intensity. Therefore, we calculated the figures for FY2022 by taking into account the consumption tax. As for the figures for FY2021 or earlier, we did not take into account the consumption tax when calculating the figures; however, we have not revised them as their impact is not significant.

* 5: CO₂ emissions from pharmaceutical wholesalers in FY2022 are not publicly available. Therefore, CO₂ emissions from pharmaceutical wholesalers in FY2021 were used in the calculation of CO₂ emissions in FY2022. As for the sales of pharmaceutical wholesalers and the sales of our products in pharmaceutical wholesalers, the sales in FY2022 were used.

* 6: The figures for FY2021 do not include 18,149 tons* of groundwater that was pumped up but not used and then discharged.

(*) Difference between raw water and treated water in the period between June and October 2021 (5 months) when groundwater use was suspended.

* 7: We refrained from the activities to prevent the spread of COVID-19.

Sumitomo Pharma ESG Data Table

*The data are basically as of the end of the fiscal year on a non-consolidated basis.

Fair Operating Practices

Reported Items	Unit	FY2022	FY2021	FY2020
Appropriate Information Disclosure and Management				
Information Security Training for All Employees	Times	1	1	1
Violations of Code of Conduct				
Number of Serious Compliance Violations	Times	0	0	0

Consumer Issues

Reported Items	Unit	FY2022	FY2021	FY2020
Initiatives to Provide Stable Supplies				
Factory in Japan	Sites	2	2	2
Distribution Center in Japan	Sites	2	2	2
Initiatives to Ensure Safety of Pharmaceuticals				
Product Recall Training in Corporate Regulatory Compliance & Quality assurance Division	Times	1	1	0
Harmful Incident Concerning Pharmaceuticals Workshops for all Employees	Times	1	1	1
Initiatives to Improve Access to Medicines				
Responding to Demands for Development of Unapproved or Off-Label Drugs	Projects	2	2	1
Collaborative Programs with Public Institutions to Control Malaria, Influenza, Antimicrobial Resistance (AMR) and Hepatitis B	Projects	7	7	6
Fight against Counterfeit Pharmaceuticals in Collaboration with International Organizations	Projects	1	1	1
Communication with Customers				
Inquiries to the Product Information Center	Times	about 30,400	about 34,000	about 41,500

Community Involvement and Development

Reported Items	Unit	FY2022	FY2021	FY2020
Stakeholder Dialogue				
Dialogue with Patients and Families				
Inquiries to the Product Information Center	Times	1,800	1,900	3,800
Dialogue with Healthcare professionals				
Inquiries to the Product Information Center	Times	26,800	29,800	34,800
Dialogue with Collaboration partners				
Competitive Open Innovation Program framework "PRISM" (Research Needs Presentation II)	Number of acceptance/ Number of applications	5 / 59	—	—
Competitive Open Innovation Program framework "PRISM" (Research Needs Presentation, Joint Creation by Young Researchers)	Number of acceptance/ Number of applications	—	2 / 15 1 Collaboration out of PRISM	2 / 15 1 Collaboration out of PRISM
Dialogue with Shareholders				
Shareholders' Meeting	Times	1	1	1
Financial Results Announcement	Times	2	2	2
Conference Call	Times	2	2	2
Meeting with Analysts and Institutional Investors	Times	92	103	76
ESG Meeting	Times	1	1	1
R&D Meeting	Times	0	1	1
Dialogue with Employees				
Employee Engagement Survey	Times	1	1	1
Response Rate	%	99	99	99
Opinions toward Management	Cases	757	778	1,063
Proposals Made to Address Issues and/or Offer Solutions at Respective Divisions/Departments	Cases	911	986	1,436
Supporting through Employee Participation				
Educational Assistance for the Next-generation				
Visiting Lectures by Employees	Schools	14	7	4
Biodiversity				
The Owls Forest Restoration Project at the Sumitomo Pharma Forest	Times	6	1	2

Sumitomo Pharma ESG Data Table

*The data are basically as of the end of the fiscal year on a non-consolidated basis.

Standards for Calculating Social Performance Indicators

Social Performance Indicators	Scope of aggregation	Calculation method, etc.
Work-related Accident Frequency Rate	(Non-consolidated); Employees (including contract employees, part-timers, temporary employees, and employees seconded to the Company) at all business sites of Sumitomo Pharma and SMP Distribution Service Co., Ltd. in Japan	Number of deaths and injuries due to occupational accidents with or without lost workdays, excluding commuting accidents, per 1,000,000 cumulative hours worked
Work-related Accident Frequency Rate * Excluding Accidents Involving Business Vehicles	(Non-consolidated); Employees (including contract employees, part-timers, temporary employees, and employees seconded to the Company) at all business sites of Sumitomo Pharma and SMP Distribution Service Co., Ltd. in Japan	Number of deaths and injuries due to occupational accidents with or without lost workdays, excluding accidents involving business vehicles and commuting accidents, per 1,000,000 cumulative hours worked
Lost-time Injuries Frequency Rate	(Non-consolidated); Employees (including contract employees, part-timers, temporary employees, and employees seconded to the Company) at all business sites of Sumitomo Pharma and SMP Distribution Service Co., Ltd. in Japan	Number of deaths and injuries due to occupational accidents with one or more lost workdays, excluding commuting accidents, per 1,000,000 cumulative hours worked
	(Consolidated) ; <FY2020 and FY2021> Employees (including contract employees, part-timers, temporary employees, and employees seconded to the Company) at all business sites of Sumitomo Pharma and the Sumitomo Pharma Group's consolidated companies in Japan and abroad (excluding one company for which an accident report was not available) <FY2022> Employees (including contract employees, part-timers, temporary employees, and employees seconded to the Company) at all business sites of Sumitomo Pharma and the Sumitomo Pharma Group's consolidated companies in Japan and abroad	
	(Contractors) ; Employees of contractors (including contract employees, part-timers, temporary employees, and employees seconded to the Company) at all business sites of the Company in Japan.	
Lost-time Injuries Frequency Rate * Excluding Accidents Involving Business Vehicles	(Non-consolidated); Employees (including contract employees, part-timers, temporary employees, and employees seconded to the Company) at all business sites of Sumitomo Pharma and SMP Distribution Service Co., Ltd. in Japan	Number of deaths and injuries due to occupational accidents with one or more lost workdays, excluding accidents involving business vehicles and commuting accidents, per 1,000,000 cumulative hours worked
Fatalities	(Consolidated) ; <FY2020 and FY2021> Employees (including contract employees, part-timers, temporary employees, and employees seconded to the Company) at all business sites of Sumitomo Pharma and the Sumitomo Pharma Group's consolidated companies in Japan and abroad (excluding one company for which an accident report was not available) <FY2022> Employees (including contract employees, part-timers, temporary employees, and employees seconded to the Company) at all business sites of Sumitomo Pharma and the Sumitomo Pharma Group's consolidated companies in Japan and abroad	Number of deaths due to occupational accidents
	(Contractors) ; Employees of contractors (including contract employees, part-timers, temporary employees, and employees seconded to the Company) at all business sites of the Company in Japan.	

Sumitomo Pharma ESG Data Table

*The data are basically as of the end of the fiscal year on a non-consolidated basis.

Standards for Calculating Environmental Performance Indicators

● Energy Consumption

Environmental performance indicators	Scope of aggregation	Calculation method, etc.
Total Energy Consumption	FY 2020: Non-consolidated (Sumitomo Pharma Co., Ltd. Only) FY2021 : Sumitomo Pharma Co., Ltd., consolidated subsidiaries in Japan, overseas consolidated subsidiaries' production sites (Sumitomo Pharma (Suzhou) Co., Ltd.) and their major R&D facilities (Sunovion Pharmaceuticals Inc.* and Sumitomo Pharma Oncology, Inc.*)	$\text{Purchased electricity}^{\#1} + (\text{purchased heat} \times \text{unit calorific value} + \text{fuel consumption}^{\#2} \times \text{unit calorific value}) \div \text{conversion factor for "MWh" to "GJ"}^{\#3}$ The unit calorific values and the types of fuel to be calculated are based on the "Act on the Rational Use of Energy." In FY2022, as for overseas non-production sites for which we do not have actual energy consumption data, we have made estimates based on the energy consumption at similar sites, using floor space ratios and other factors. #1 It includes solar power generated at our business sites. #2 Gasoline consumption of business vehicles includes only domestic gasoline consumption for FY2021 and earlier, and all domestic and overseas gasoline consumption for FY2022 and beyond. #3 3.6GJ/MWh
Non-renewable Energy Consumption	FY2022 : Consolidated (Sumitomo Pharma Co., Ltd., consolidated subsidiaries in Japan, overseas consolidated subsidiaries)	Amount of energy consumption derived from non-renewable energy sources out of the total energy consumption
Renewable Energy Consumption	*Sunovion Pharmaceuticals Inc. and Sumitomo Pharma Oncology, Inc.	Amount of energy consumption derived from renewable energy sources out of the total energy consumption
Amount of Purchased Electricity Derived from Renewable Energy Sources	Sumitomo Pharma America, Inc. as a result of the reorganization of our U.S. group companies effective as of July 1, 2023.	Amount of renewable energy-derived electricity purchased out of the renewable energy consumption
Amount of Generated Electricity at the Solar Power Generating Systems		Amount of solar power generated by solar power generation systems at our business sites out of the renewable energy consumption

Sumitomo Pharma ESG Data Table

*The data are basically as of the end of the fiscal year on a non-consolidated basis.

● CO₂ Emissions

Environmental performance indicators	Scope of aggregation	Calculation method, etc.
Scope 1 (from Energy Sources) + Scope 2 (Market-Based) Total Emissions		Total of Scope 1 (from Energy Sources) and Scope 2 (Market-Based) emissions
Scope 1 (from Energy Sources) Emissions	FY2020: Non-consolidated (Sumitomo Pharma Co., Ltd. Only) FY2021: Sumitomo Pharma Co., Ltd., consolidated subsidiaries in Japan, overseas consolidated subsidiaries' production sites (Sumitomo Pharma (Suzhou) Co., Ltd.) and their major R&D facilities (Sunovion Pharmaceuticals Inc.* and Sumitomo Pharma Oncology, Inc.*)	Fuel consumption ^{#4} × fuel unit calorific value × fuel CO ₂ emissions factor The unit calorific values and CO ₂ emissions factors are based on "Greenhouse Gas Emissions Accounting, Reporting, and Disclosure System" which is provided in the "Act on Promotion of Global Warming Countermeasures." In FY2022, as for overseas non-production sites for which we do not have actual fuel consumption figures, we have made estimates based on the fuel consumption at similar sites, using floor space ratios and other factors. ^{#4} Gasoline consumption of business vehicles includes only domestic gasoline consumption for FY2021 and earlier, and all domestic and overseas gasoline consumption for FY2022 and beyond.
Scope 2 (Market-Based) Emissions	FY2022: Consolidated (Sumitomo Pharma Co., Ltd., consolidated subsidiaries in Japan, overseas consolidated subsidiaries) *Sunovion Pharmaceuticals Inc. and Sumitomo Pharma Oncology, Inc. changed their trade names to Sumitomo Pharma America, Inc. as a result of the reorganization of our U.S. group companies effective as of July 1, 2023.	Purchased electricity ^{#5} × electricity CO ₂ emissions factor ^{#6} + purchased heat × heat CO ₂ emissions factor ^{#7} ^{#5} It includes solar power generated at our business sites. ^{#6} For domestic sites, adjusted emissions factors from "Emission Factors by Power Suppliers (for the calculation of GHG emissions by specified emitters)" published by the Ministry of the Environment and the Ministry of Economy, Trade and Industry of Japan, for overseas sites, the emissions factors by country for 2019 published by the International Energy Agency (IEA). However, we use values provided by Sumitomo Chemical Co., Ltd. for sites located on the premises of Sumitomo Chemical Co., Ltd. ^{#7} Values are based on "Greenhouse Gas Emissions Accounting, Reporting, and Disclosure System" which is provided in "Act on Promotion of Global Warming Countermeasures." However, we use values provided by Sumitomo Chemical Co., Ltd. for sites located on the premises of Sumitomo Chemical Co., Ltd. In FY2022, as for overseas non-production sites for which we do not have actual purchased electricity amounts, we have made estimates based on purchased electricity amounts at similar sites, using floor space ratios and other factors.
Scope 3 Emissions	Refer to each category	Total of Category 1 emissions to Category 15 emissions Ministry of the Environment DB: Ministry of the Environment's "Emission Intensity Database for Calculating Greenhouse Gas Emissions etc. of Organizations through their Supply Chains" (FY2020 emissions; Ver. 3.1 applied, FY2021 emissions; Ver. 3.2 applied, FY2022 emissions; Ver. 3.3 applied) LCI-DB: LCI Database IDEAv2 (for calculation of supply chain GHG emissions)
Category 1 (Purchased Goods and Services)	Non-consolidated	Calculated by multiplying the purchase price of raw and packaging materials for products and purchased products and outsourced manufacturing costs by the emissions intensity in Japanese Ministry of the Environment database
Category 2 (Capital Goods)	Consolidated basis (The Sumitomo Pharma Group including overseas subsidiaries)	Calculated by multiplying the acquisition price of the fixed asset by the emissions intensity in Japanese Ministry of the Environment database
Category 3 (Fuel- and Energy-Related Activities not Included in Scope 1 or Scope 2)	Non-consolidated	Calculated by multiplying purchased electricity and steam by the emissions intensity in Japanese Ministry of the Environment database and purchased fuel by the emissions intensity in Carbon Footprint database or lifecycle inventory (LCI) database
Category 4 (Upstream Transportation and Distribution)	Transport in Japan, on a non-consolidated basis	Calculated by multiplying ton/kilometer for the transportation scenario by the emissions intensity in Japanese Ministry of the Environment database and LCI database

Sumitomo Pharma ESG Data Table

*The data are basically as of the end of the fiscal year on a non-consolidated basis.

Category 5 (Waste Generated in Operations)	Non-consolidated	Calculated by multiplying the weight of waste according to type and processing method by the emissions intensity in Japanese Ministry of the Environment database
Category 6 (Business Travel)	Non-consolidated	Calculated by multiplying business travel expenses paid by the emissions intensity in Japanese Ministry of the Environment database
Category 7 (Employee Commuting)	Non-consolidated	Calculated by multiplying commuting cost according to transportation means by the emissions intensity in Japanese Ministry of the Environment database
Category 8 (Upstream Leased Assets)	—	—
Category 9 (Downstream Transportation and Distribution)	Non-consolidated	Calculated by multiplying CO ₂ emissions (estimate) per unit of sales in major drug wholesalers by sales of our products in drug wholesale segment
Category 10 (Processing of Sold Products)	—	—
Category 11 (Use of Sold Products)	Non-consolidated	Calculated by multiplying HFC amount in pharmaceutical MDIs (metered dose inhalers) sold by GWP
Category 12 (End-of-Life Treatment of Sold Products)	Non-consolidated	Calculated by multiplying the weight of the container and packaging according to material based on "Act on the Promotion of Sorted Collection and Recycling of Containers and Packaging " by the emissions intensity in Japanese Ministry of the Environment database
Category 13 (Downstream Leased Assets)	Non-consolidated	Calculated by multiplying the energy consumption of the building asset owned and rented out by the conversion factors based on "Greenhouse Gas Emissions Accounting, Reporting, and Disclosure System" which is provided in "Act on Promotion of Global Warming Countermeasures"
Category 14 (Franchises)	—	—
Category 15 (Investments)	—	—

Sumitomo Pharma ESG Data Table

*The data are basically as of the end of the fiscal year on a non-consolidated basis.

● Amount of Water Withdrawal and Wastewater Discharged

Environmental performance indicators	Scope of aggregation	Calculation method, etc.
Total Amount of Water Withdrawal (consolidated)	Consolidated (Sumitomo Pharma Co., Ltd., consolidated subsidiaries in Japan, overseas consolidated subsidiaries)	Total amount of water withdrawal of tap water, industrial water, ground water, and other (pure water)
Total Amount of Water Discharged (consolidated)	However, small offices such as branches and business offices are excluded. In addition, overseas consolidated subsidiaries that do not have production sites or major research facilities are excluded from the scope because they have only small offices.	Total amount of water discharged to rivers and to sewerage. *As for sites that do not measure the amount of water discharged, the amount of water withdrawal is considered as the water discharged.
Total Amount of Water Withdrawal (non-consolidated)	Non-consolidated (Only Sumitomo Pharma Co., Ltd.)	Total amount of water withdrawal of tap water, industrial water, ground water, and other (pure water).
Total Amount of Water Discharged (non-consolidated)	However, small offices such as branches and business offices are excluded.	Total amount of water discharged to rivers and to sewerage. *As for sites that do not measure the amount of water discharged, the amount of water withdrawal is considered as the water discharged.

● Raw Material Consumption

Environmental performance indicators	Scope of aggregation	Calculation method, etc.
Raw Materials for Products (excluding Metals)	Non-consolidated	Amount of consumed raw materials for products (excluding metals)
Raw Materials for Products (Metals)		Amount of consumed raw metals for products (metals)
Product Containers and Packaging Materials		Total amount of product containers and packaging materials used for products sold in Japan

● PRTR Substances and VOC Substances

Environmental performance indicators	Scope of aggregation	Calculation method, etc.
PRTR Substances	Non-consolidated	Amount of PRTR substances handled for which we submitted reports under the Japanese Act on Confirmation, etc. of Release Amounts of Specific Chemical Substances in the environment and Promotion of Improvements to the Management Thereof (PRTR Law)
VOC Substances		Total amount of substance annually handled in quantities of 1 ton or more, out of 55 substances* *The number of substances excluding PRTR substances, out of 101 volatile organic compounds (VOCs), i.e. the 100 major VOCs listed by the Ministry of the Environment plus n-propyl alcohol

Sumitomo Pharma ESG Data Table

*The data are basically as of the end of the fiscal year on a non-consolidated basis.

●Waste

Environmental performance indicators	Scope of aggregation	Calculation method, etc.
Total Amount of Waste Generated	Non-consolidated However, branches and business offices are excluded.	Total amount of by-products and other unwanted materials generated as a result of our normal business activities (including valuable resources)
Amount Recycled		Amount of waste reused, recycled, or converted to valuable resources out of the total amount of waste generated
Recycling Rate		Percentage of amount of waste recycled to the total amount of waste generated
Amount of Final Disposal		Amount of waste finally disposed of by landfill out of the total amount of waste generated
Final Disposal Rate		Percentage of waste finally disposed of to the total amount of waste generated
Amount of Hazardous Waste Generated		Amount of hazardous waste (waste classified as specially-controlled industrial waste generated) out of the total amount of waste generated
Amount of Hazardous Waste Recycled		Amount of hazardous waste reused, recycled, or converted into valuable resources out of the total amount of hazardous waste generated
PRTR Substances	Non-consolidated	Atmospheric emission of PRTR substances that we reported under the PRTR Law
Waste Containing High Levels of PCB in Storage	Non-consolidated	Total amount/number of waste containing high levels of PCB in storage
Waste Containing Low Levels of PCB in Storage or in Use		Total number of devices containing low levels of PCB that are stored or continuously used

●Other Indicators

· The data are basically on a non-consolidated basis.